200 related articles for article (PubMed ID: 34871905)
41. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication
Shytaj IL; Fares M; Gallucci L; Lucic B; Tolba MM; Zimmermann L; Adler JM; Xing N; Bushe J; Gruber AD; Ambiel I; Taha Ayoub A; Cortese M; Neufeldt CJ; Stolp B; Sobhy MH; Fathy M; Zhao M; Laketa V; Diaz RS; Sutton RE; Chlanda P; Boulant S; Bartenschlager R; Stanifer ML; Fackler OT; Trimpert J; Savarino A; Lusic M
mBio; 2022 Apr; 13(2):e0370521. PubMed ID: 35229634
[TBL] [Abstract][Full Text] [Related]
42. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
Uzunova K; Filipova E; Pavlova V; Vekov T
Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
[TBL] [Abstract][Full Text] [Related]
43. RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery.
Zhu W; Chen CZ; Gorshkov K; Xu M; Lo DC; Zheng W
SLAS Discov; 2020 Dec; 25(10):1141-1151. PubMed ID: 32660307
[TBL] [Abstract][Full Text] [Related]
44. Genome-scale metabolic modeling reveals SARS-CoV-2-induced metabolic changes and antiviral targets.
Cheng K; Martin-Sancho L; Pal LR; Pu Y; Riva L; Yin X; Sinha S; Nair NU; Chanda SK; Ruppin E
Mol Syst Biol; 2021 Nov; 17(11):e10260. PubMed ID: 34709707
[TBL] [Abstract][Full Text] [Related]
45. Sulforaphane exhibits antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses in vitro and in mice.
Ordonez AA; Bullen CK; Villabona-Rueda AF; Thompson EA; Turner ML; Merino VF; Yan Y; Kim J; Davis SL; Komm O; Powell JD; D'Alessio FR; Yolken RH; Jain SK; Jones-Brando L
Commun Biol; 2022 Mar; 5(1):242. PubMed ID: 35304580
[TBL] [Abstract][Full Text] [Related]
46. Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2
Gammeltoft KA; Zhou Y; Duarte Hernandez CR; Galli A; Offersgaard A; Costa R; Pham LV; Fahnøe U; Feng S; Scheel TKH; Ramirez S; Bukh J; Gottwein JM
Antimicrob Agents Chemother; 2021 Aug; 65(9):e0268020. PubMed ID: 34097489
[TBL] [Abstract][Full Text] [Related]
47. The NSP14/NSP10 RNA repair complex as a Pan-coronavirus therapeutic target.
Rona G; Zeke A; Miwatani-Minter B; de Vries M; Kaur R; Schinlever A; Garcia SF; Goldberg HV; Wang H; Hinds TR; Bailly F; Zheng N; Cotelle P; Desmaële D; Landau NR; Dittmann M; Pagano M
Cell Death Differ; 2022 Feb; 29(2):285-292. PubMed ID: 34862481
[TBL] [Abstract][Full Text] [Related]
48. Single cell resolution of SARS-CoV-2 tropism, antiviral responses, and susceptibility to therapies in primary human airway epithelium.
Fiege JK; Thiede JM; Nanda HA; Matchett WE; Moore PJ; Montanari NR; Thielen BK; Daniel J; Stanley E; Hunter RC; Menachery VD; Shen SS; Bold TD; Langlois RA
PLoS Pathog; 2021 Jan; 17(1):e1009292. PubMed ID: 33507952
[TBL] [Abstract][Full Text] [Related]
49. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
[TBL] [Abstract][Full Text] [Related]
50. Antiviral activity of digoxin and ouabain against SARS-CoV-2 infection and its implication for COVID-19.
Cho J; Lee YJ; Kim JH; Kim SI; Kim SS; Choi BS; Choi JH
Sci Rep; 2020 Oct; 10(1):16200. PubMed ID: 33004837
[TBL] [Abstract][Full Text] [Related]
51. AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2
Good SS; Westover J; Jung KH; Zhou XJ; Moussa A; La Colla P; Collu G; Canard B; Sommadossi JP
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33558299
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of coronavirus infection by a synthetic STING agonist in primary human airway system.
Zhu Q; Zhang Y; Wang L; Yao X; Wu D; Cheng J; Pan X; Liu H; Yan Z; Gao L
Antiviral Res; 2021 Mar; 187():105015. PubMed ID: 33444702
[TBL] [Abstract][Full Text] [Related]
53. Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir.
Martin R; Li J; Parvangada A; Perry J; Cihlar T; Mo H; Porter D; Svarovskaia E
Antiviral Res; 2021 Apr; 188():105033. PubMed ID: 33549572
[TBL] [Abstract][Full Text] [Related]
54. Off-Target
Xu Y; Barauskas O; Kim C; Babusis D; Murakami E; Kornyeyev D; Lee G; Stepan G; Perron M; Bannister R; Schultz BE; Sakowicz R; Porter D; Cihlar T; Feng JY
Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33229429
[TBL] [Abstract][Full Text] [Related]
55. Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.
White KM; Rosales R; Yildiz S; Kehrer T; Miorin L; Moreno E; Jangra S; Uccellini MB; Rathnasinghe R; Coughlan L; Martinez-Romero C; Batra J; Rojc A; Bouhaddou M; Fabius JM; Obernier K; Dejosez M; Guillén MJ; Losada A; Avilés P; Schotsaert M; Zwaka T; Vignuzzi M; Shokat KM; Krogan NJ; García-Sastre A
Science; 2021 Feb; 371(6532):926-931. PubMed ID: 33495306
[TBL] [Abstract][Full Text] [Related]
56. The
Hu Y; Meng X; Zhang F; Xiang Y; Wang J
Emerg Microbes Infect; 2021 Dec; 10(1):317-330. PubMed ID: 33560940
[TBL] [Abstract][Full Text] [Related]
57. Remdesivir: A Closer Look at Its Effect in COVID-19 Pandemic.
Taha HR; Keewan N; Slati F; Al-Sawalha NA
Pharmacology; 2021; 106(9-10):462-468. PubMed ID: 34515227
[TBL] [Abstract][Full Text] [Related]
58. A Review on Remdesivir: A Broad-spectrum Antiviral Molecule for Possible COVID-19 Treatment.
Khazir J; Maqbool T; Mir BA
Mini Rev Med Chem; 2021; 21(17):2530-2543. PubMed ID: 33596800
[TBL] [Abstract][Full Text] [Related]
59. Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir.
Camprubí D; Gaya A; Marcos MA; Martí-Soler H; Soriano A; Mosquera MDM; Oliver A; Santos M; Muñoz J; García-Vidal C
Int J Infect Dis; 2021 Mar; 104():379-381. PubMed ID: 33359065
[TBL] [Abstract][Full Text] [Related]
60. Endoplasmic reticulum stress and NF-kB activation in SARS-CoV-2 infected cells and their response to antiviral therapy.
Bartolini D; Stabile AM; Vacca C; Pistilli A; Rende M; Gioiello A; Cruciani G; Galli F
IUBMB Life; 2022 Jan; 74(1):93-100. PubMed ID: 34390301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
